Vivanza Biosciences Ltd (VIVANZA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Vivanza Biosciences Ltd on NSE and BSE, with an AI summary of each filing.
Non-applicability of Reg 23 (9) of SEBI (LODR) Regulation, 2015 for the Quarter on 30th September, 2026.
Others (Uncategorized) · 29 Oct 2026, 10:04 pm
Vivanza Biosciences Confirms Non-Applicability of Related Party Disclosures for Q2 FY27 Vivanza Biosciences announced that submission of Related Party Transactions disclosure under Regulation 23(9) of SEBI LODR Regulations is not applicable for the quarter and half-year ended 30th Sep'26. Under Regulation 15(2), corporate governance provisions are exempt for companies with paid-up equity capital under Rs 10 Cr and net worth under Rs 25 Cr. As of 31st Mar'26, the company's paid-up equity share capital stood at Rs 4.00 Cr, while its net worth was Rs 4.40 Cr, placing it below the mandatory regulatory reporting thresholds.
Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve unaudited standalone and ....
Intimation · 03 Nov 2026, 5:30 am
Vivanza Biosciences Board Meeting Scheduled for 3rd Nov'26 to Consider Q2 Results Vivanza Biosciences Limited has scheduled a meeting of its Board of Directors on 3rd Nov'26 to consider and approve the unaudited standalone and consolidated financial results, along with the limited review report, for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in company securities by designated persons and key managerial personnel remains closed until 48 hours after the declaration of the financial results.
Non applicability of the statements of Variation and Deviation under regulation 32 of SEBI LODR Regulation, 2015 as Company has not raised any further funds, hence statements of Deviation ....
Others (Uncategorized) · 08 Oct 2026, 5:00 pm
Vivanza Biosciences Confirms Non-Applicability of SEBI Regulation 32 Statement of Deviation Vivanza Biosciences Limited informed BSE on 8th Oct'26 regarding the non-applicability of the Statement of Deviation or Variation under Regulation 32 of SEBI (LODR) Regulations, 2015. The company confirmed that it has not raised any further capital through public issues, rights issues, preferential issues, or Qualified Institutions Placements (QIP), rendering the submission of a deviation or variation statement non-applicable.
Voting Result for the 44th Annual General Meeting of the Company
Annual General Meeting · 12 Sept 2026, 6:55 pm
Revised Outcome of the 44th Annual General Meeting of the Vivanza Biosciences Limited
Annual General Meeting · 12 Sept 2026, 5:19 pm
Outcome of the 44th Annual General Meeting of the Members of the Vivanza Biosciences Limited.
Annual General Meeting · 11 Sept 2026, 9:34 pm
Please find enclosed newspaper advertisement w.r.t Notice of 44th AGM of the Company and e-voting information.
Annual General Meeting · 20 Aug 2026, 5:12 pm
Annual Report for the Financial Year 2025-2026 of the Company.
Others (Uncategorized) · 19 Aug 2026, 5:28 pm
Notice of the 44th Annual General Meeting and Annual Report of the Company for the Financial Year 2025-26
Annual General Meeting · 19 Aug 2026, 5:15 pm
The Board of Directors of the Company at its meeting held on Monday, August 17, 2026, at the Registered Office, inter alia, considered and approved: 1. Director's Report, Secretarial Audit ....
Outcome · 17 Aug 2026, 9:36 pm
Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 ,inter alia, to consider and approve 1) To consider and approve ....
Intimation · 12 Aug 2026, 11:38 pm
Pursuant to Regulation 32 of the SEBI(LODR) Regulation, 2015 Read with SEBI circular dated 24th December, 2019 regarding the submission of the statement of deviation or variation from the ....
Others (Uncategorized) · 08 Aug 2026, 5:26 pm
Vivanza Biosciences Confirms No Fund Raising, Deviation Statement Not Applicable Vivanza Biosciences Limited informed the exchange on 08 Aug'26 that the submission of a Statement of Deviation or Variation is not applicable. The company confirmed it has not raised funds through any public issue, rights issue, preferential issue, or Qualified Institutions Placement (QIP). This filing is pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015, clarifying that there are no proceeds from such issues to report utilization against.
Approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 and other items .
Financial Result · 07 Aug 2026, 6:59 pm
Vivanza Biosciences Reports Q1 FY27 Results, Profit Rebounds Sequentially Vivanza Biosciences reported standalone results for the quarter ended 30 Jun'26, showing a profit after tax of ₹14.51 Lacs, a significant turnaround from the ₹26.61 Lacs loss in Q4 FY26 and a 683% YoY increase from ₹1.86 Lacs. Revenue from operations grew 16.9% YoY and 59.1% QoQ to ₹914.09 Lacs. On a consolidated basis, Q1 FY27 profit after tax was ₹14.67 Lacs, recovering from a ₹45.08 Lacs loss in the prior quarter and up 68.6% YoY from ₹8.70 Lacs.
Approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 and other items .
Financial Result · 07 Aug 2026, 6:58 pm
Vivanza Biosciences Board Approves Financial Results for Q1 FY27 Vivanza Biosciences reported its unaudited results for the quarter ended 30th Jun'26. On a standalone basis, revenue was ₹914.09 Lacs, up 16.9% YoY and 59.1% QoQ. Profit after tax (PAT) stood at ₹14.51 Lacs, a significant turnaround from a loss of ₹26.61 Lacs in the prior quarter and up from ₹1.86 Lacs YoY. Consolidated revenue was ₹928.97 Lacs, with a PAT of ₹14.67 Lacs, reversing a QoQ loss of ₹45.08 Lacs. Basic EPS for the quarter was ₹0.04.
Approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2026, along with year-to-date figures for the period from 1st April, 2026, to 30th ....
Outcome · 07 Aug 2026, 6:41 pm
Vivanza Biosciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lacs) ■ Revenue: 929 (+3.9% YoY | +46.0% QoQ) ■ EBITDA: -7.9 (Profit to Loss YoY | +66.2% QoQ) ■ EBITDA Margin (%): -0.8 (Profit to Loss YoY | +282 bps QoQ) ■ PAT: 14.7 (+68.6% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.04 (+100.0% YoY | Loss to Profit QoQ)
Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 ,inter alia, to consider and approve 1. Unaudited Standalone ....
Intimation · 01 Aug 2026, 5:30 am
Vivanza Biosciences Board to Review Q1 FY27 Results on 01-Aug Vivanza Biosciences has scheduled a Board of Directors meeting for 01-Aug'26 to consider and approve its unaudited standalone and consolidated financial results for the quarter ending 30-Jun'26. The meeting will also take note of disclosures of interest and declarations from independent directors. The company has already closed the trading window for designated persons, which will reopen 48 hours after the financial results are declared. The announcement was made to the BSE on 28-Jul'26.
we hereby declared that statutory auditor of the company M/s Shivam Soni & co, Chartered Accountant (FRN: 152477W) have issued an Audit Report with unmodified opinion on the Audited Financial ....
Others (Uncategorized) · 14 Jul 2026, 4:03 pm
VIVANZA BIOSCIENCES: UNMODIFIED AUDIT OPINION FOR FY26 RESULTS Vivanza Biosciences (BSE: 530057) announced its statutory auditors, M/S. Shivam Soni & Co, have issued an audit report with an unmodified opinion. This declaration, filed on 11th Jul'26, pertains to the audited financial results for the quarter and year ended 31st Mar'26. An unmodified opinion, often termed a "clean report," indicates the financial statements are presented fairly and comply with accounting standards, providing a positive signal to investors regarding the company's financial reporting integrity.
pursuant to regulation 30 of the SEBI(LODR) Regulations, 2015 appointmnet of Mr. Vishal Sureshbhai Katarmal as a Company Secretary and Compliance Officer has been approved with effect from ....
Change in Management · 09 Jul 2026, 9:21 pm
Vivanza Biosciences Appoints New Company Secretary and Compliance Officer Vivanza Biosciences (BSE: 530057) has appointed Mr. Vishal Sureshbhai Katarmal as Company Secretary and Compliance Officer, effective from 09th Jul'26. The appointment was approved by the Board of Directors in their meeting held on the same day. Mr. Katarmal is an Associate Member of the Institute of Company Secretaries of India. This key managerial personnel change is a mandatory disclosure under SEBI's Listing Obligations and Disclosure Requirements regulations.
Pursuant to Regulation 29 and other applicable provisions of the SEBI (LODR) Regulations, 2015, this is to inform you that a meeting of the Board of Directors of the Company was held on ....
Others (Uncategorized) · 09 Jul 2026, 9:14 pm
Vivanza Biosciences Board Meeting Highlights Key Appointments and Kyrgyz Republic Project Vivanza Biosciences announced outcomes from its board meeting on 09th Jul'26. Key decisions included noting an agreement for strategic cooperation to establish a Plastic Film Manufacturing Project in the Kyrgyz Republic. The board also approved the appointment of Mr. Vishal Sureshbhai Katarmal as the new Company Secretary and Compliance Officer, effective immediately. Additionally, the board authorized the transfer of 300 unverified equity shares from the Unclaimed Suspense Account to the rightful owner and noted the filing of the DPT-3 Return of Deposit.
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Execution of Strategic Corporation, Investment & Technology Transfer Agreement
Others (Uncategorized) · 29 Jun 2026, 8:47 pm
Vivanza Biosciences Signs Strategic Agreement for Kyrgyz Republic Expansion Vivanza Biosciences signed a Strategic Cooperation, Investment & Technology Transfer Agreement on 29 Jun'26 with Mr. Kalybek Uulu Bekturgan to establish a Plastic Film Manufacturing Project in the Kyrgyz Republic. The non-binding agreement's scope includes technology transfer, government liaison, investment facilitation, and the potential for a future Joint Venture. While no monetary consideration is involved at present, the deal aims to strengthen Vivanza's international presence, expand export markets, and create long-term growth opportunities, although immediate financial benefits are not quantifiable.
Pursuant to Reg 29 and other applicable provisions of SEBI LODR Reg, 2015 this is to inform you that a meeting of the Board of Directors of the Company held on 18th June 2026 has considered ....
Change in Management · 18 Jun 2026, 7:37 pm
Vivanza Biosciences Appoints New Director and Internal Auditor Vivanza Biosciences Limited's board, on 18th Jun'26, approved two key appointments. Mr. Hemant Amrish Parikh was appointed as an Additional Non-Executive Non-Independent Director, effective immediately. Mr. Parikh is a chemical engineer with over 30 years of pharmaceutical industry experience. Additionally, M/s. Dharti Shah & Co., Chartered Accountants, were appointed as the Internal Auditor for the financial year 2026-2027. Both appointments are subject to applicable legal provisions and shareholder approvals where necessary.
1.The Board of Directors of the Company, at its meeting held today, has considered and approved the following transactions. The meeting of the Board of Directors of the Company commenced ....
Outcome · 18 Jun 2026, 7:31 pm
Vivanza Biosciences Board Appoints New Director and Internal Auditor Vivanza Biosciences' board, at its meeting on 18th Jun'26, appointed Mr. Hemant Amrish Parikh as an Additional Non-Executive Non-Independent Director for a five-year term, subject to shareholder approval. Mr. Parikh, a chemical engineer with over 30 years of pharmaceutical industry experience, is not debarred by any SEBI order. The board also appointed M/s. Dharti Shah & Co. as the Internal Auditor for FY27. Additionally, the company approved the transfer of 300 shares from its Unclaimed Suspense Account to the rightful shareholder.
Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2026 ,inter alia, to consider and approve 1.To authorise Mr. Sarang ....
Intimation · 18 Jun 2026, 5:30 am
Vivanza Biosciences Board Meeting to Approve Key Appointments and Financials Vivanza Biosciences has scheduled a board meeting on 18th Jun'26 to discuss several key items. The agenda includes authorizing the signing of the financial statements for the year ended 31st Mar'26. The board will also consider the appointment of M/s. Dharti Shah & Co. as the internal auditor for FY 2026-2027 and the appointment of Mr. Hemant Amrish Parikh as a Non-Executive Non-Independent Director. Additionally, the transfer of unverified shares to an Unclaimed Suspense Account will be reviewed.
This is to inform you that as per Regulation 15(2) of SEBI (LODR) Regulations, 2015, Corporate Governance and the above mentioned provisions such as Regulation 23(9) of SEBI (LODR) Regulations, ....
Others (Uncategorized) · 08 May 2026, 4:46 am
Vivanza Biosciences: RPT Disclosure Not Applicable for Quarter Ended Mar'26 Vivanza Biosciences (BSE: 530057) announced that the disclosure of Related Party Transactions under SEBI Regulation 23(9) is not applicable for the quarter and year ended 31st Mar'26. This exemption is due to its paid-up equity capital of ₹4.00 crore and net worth of ₹4.02 crore as of 31st Mar'25, both of which are below the SEBI-mandated thresholds of ₹10 crore and ₹25 crore, respectively, for such compliance. The company will comply within six months if the regulation becomes applicable later.
Audited Standalone Financial Results for the Quarter and Year ended on 31st March, 2026, Took note of resignation of Hemant A. Parikh as an MD and Chaitra Arora a CS, Reconstitution of ....
Financial Result · 08 May 2026, 4:39 am
VIVANZA BIOSCIENCES LIMITED - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lacs) ■ Revenue: 636 (+1217.4% YoY | -85.9% QoQ) ■ EBITDA: -23.3 (+75.5% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -3.7 (+19370 bps YoY | Profit to Loss QoQ) ■ PAT: -45.1 (+54.8% YoY | Profit to Loss QoQ) ■ EPS (INR): -0.11 (+56.0% YoY | Profit to Loss QoQ)